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ABSTRACT
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-
related deaths worldwide. There is increasing interest in developing specific markers 
to serve as predictors of response to sorafenib and to guide targeted therapy. Using a 
sequencing platform designed to study somatic mutations in a selection of 112 genes 
(HepatoExome), we aimed to characterize lesions from HCC patients and cell lines, 
and to use the data to study the biological and mechanistic effects of case-specific 
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targeted therapies used alone or in combination with sorafenib. We characterized 331 
HCC cases in silico and 32 paired samples obtained prospectively from primary tumors 
of HCC patients. Each case was analyzed in a time compatible with the requirements 
of the clinic (within 15 days). In 53% of the discovery cohort cases, we detected 
unique mutational signatures, with up to 34% of them carrying mutated genes with 
the potential to guide therapy. In a panel of HCC cell lines, each characterized by 
a specific mutational signature, sorafenib elicited heterogeneous mechanistic and 
biological responses, whereas targeted therapy provoked the robust inhibition of 
cell proliferation and DNA synthesis along with the blockage of AKT/mTOR signaling. 
The combination of sorafenib with targeted therapies exhibited synergistic anti-
HCC biological activity concomitantly with highly effective inhibition of MAPK and 
AKT/mTOR signaling. Thus, somatic mutations may lead to identify case-specific 
mechanisms of disease in HCC lesions arising from multiple etiologies. Moreover, 
targeted therapies guided by molecular characterization, used alone or in combination 
with sorafenib, can effectively block important HCC disease mechanisms.
INTRODUCTION
Hepatocellular carcinoma (HCC hereafter) is the 
fifth most prevalent cancer and the third most frequent 
cause of cancer-related death worldwide, with up to 800K 
deaths in 2012 [1]. It is a disease of increasing incidence 
and the leading cause of death among patients with 
cirrhosis. It can be related to multiple etiologies, including 
infections with hepatitis B or C viruses (HBV and HCV, 
respectively), alcohol and nonalcoholic steatohepatitis 
[2, 3]. HCC diagnosis is mainly guided by radiological 
criteria with only one third of patients being diagnosed 
at early stages (namely BCLC-0 and BCLC-A) [4]. This 
makes them candidates for liver transplantation, surgical 
resection or percutaneous ablation, which is associated 
with a 5-year recurrence rate of 70-80% [5, 6]. Outcomes 
are even worse for patients with intermediate or advanced 
stages (BCLC-B and C, respectively) [7]. Generally, 
these patients will receive specific therapy that includes 
transarterial chemoembolization (for BCLC-B patients), 
which yields an increase in median survival from 16 to 
24 months [8], or therapy with sorafenib (for BCLC-C 
patients). Sorafenib is an oral multitarget kinase inhibitor 
that can increase median survival from 7.9 to 10.7 months 
[9]. The modest but significant clinical benefit from 
sorafenib has prompted further clinical trials based on the 
comparison of sorafenib with other inhibitors, alone or in 
combination, as first- and second-line treatment, but these 
have yielded poor results [10], [11]. It is important to note 
that we currently lack molecular evidence to optimize the 
clinical benefits that HCC patients may gain from any of 
these therapies.
From a genomic perspective, HCC is a very 
heterogeneous disease, possibly reflecting the multiple 
etiologies causing this type of cancer [12]. Much effort 
has been made to characterize HCC molecularly. On 
one hand, whole-transcriptome analyses have revealed 
deregulated expression of signaling molecules, such 
as the overexpression of well-known oncogenic genes 
and pathways like MET (in 40-50% of patients) [13], 
IGF2 (in 10%) [14, 15], WNT/β-catenin (in 25%) [16] 
and TGF-β [17]. These transcriptome findings helped 
establish a molecular classification of two different HCC 
subtypes: 1) a proliferation class, with activated signaling 
pathways like TGF-β, MYC or PI3K-AKT, promoting 
worse clinical outcomes; and 2) a non-proliferation 
class, displaying activated WNT signaling in up to 25% 
of cases [17]. On the other hand, recent next-generation 
sequencing (NGS) mutational studies have confirmed the 
heterogeneous nature of HCC. The main genes recurrently 
found to have mutations are tumor suppressors like TP53, 
which affects 20-24% of the patients analyzed [12, 18], 
and those involved in the WNT pathway, like CTNNB1, 
which is detected in 33-37% of cases, or AXIN1 (in 11-
15% of cases) [11, 12, 18]. Somatic mutations have 
also been found in genes like ARID1A (in 13-17% of 
patients) and CDKN2A (7-9%), and to a lesser extent in 
IRF2 (5%), KRAS (1.6%) and PIK3CA (1.6%) [12, 18]. 
Finally, mutations affecting the TERT promoter associated 
with increased TERT expression have been described as 
an early event in HCC (60% of cases) [19]. However, 
our knowledge of the molecular mechanisms that can 
participate in the development of HCC has not so far 
improved our ability to diagnose or treat this disease.
Taking advantage of the NGS data already 
generated for HCC, in this study we aimed to characterize 
HCC lesions to potentially use the data for diagnosis 
and targeted therapy. To this end, we have designed a 
targeted approach based on the mutational analysis of 
a specific selection of 112 genes, which enabled us to 
prospectively characterize HCC cases from patients with 
multiple etiologies and in a time that was compatible 
with the requirements of the clinic (within 15 days). 
Moreover, we used the data to study the biological and 
mechanistic effects of case-specific therapies used alone 
or in combination with sorafenib in a panel of HCC cell 
lines. This approach can enable the generation of genomic 
data in early stage HCCs that could be useful for tracking 
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disease evolution and progression, and that might serve as 
a rationale for targeted therapy.
RESULTS
A targeted approach to characterizing specific 
mutational HCC signatures in silico
There is great interest in developing novel 
approaches for HCC diagnosis as well as in improving 
our ability to manage patients with advanced diseases. 
We hypothesized that case-specific mutational signatures 
within HCC cases could act as markers of important 
oncogenic mechanisms involved in HCC activities, 
including responses to sorafenib. To explore such specific 
mechanisms, we designed a targeted NGS approach that 
focused on mutations affecting the exonic regions of a 
selection of 112 genes (HepatoExome hereafter). For this 
purpose, we used the mutational data already available 
from a cohort of 41 cases comprising samples from 
patients and cell lines (see Supplementary Table 1). Within 
our selection of genes, we included those already known to 
play a potential role in the disease (i.e., WNT, B-CATENIN 
and TP53) and others that have been implicated in specific 
signaling networks and that might serve as targets for 
therapy, e.g., JAK-STAT, PI3K-mTOR, MAPK and 
Receptors with Tyrosine Kinase Activity (RTKs). To 
assess the feasibility of our approach to detecting mutated 
genes in HCC samples, we studied in silico the mutations 
in genes included in the HepatoExome in an independent 
cohort of 331 samples from HCC patients with a known 
mutational profile (validation cohort in Supplementary 
Table 1). In this setting, we were able to detect relevant 
mutated genes in 69.2% of the cases. The most frequently 
mutated genes detected in the validation cohort samples 
are described in Figure 1A and Supplementary Table 2. 
Amongst these, we detected mutations affecting the WNT 
pathway (CTNNB1, AXIN1 and APC), PI3K-mTOR 
(TSC2, TSC1, PTEN and MTOR), RTKs (e.g., FLT1, 
EGFR, INSR and RET), chromatin regulation and repair 
(HNF1A, ATM, ATR and PRKDC) and TP53. Interestingly, 
these hits belonged to multiple signaling pathways (Figure 
1B), which may reflect the molecular heterogeneity 
associated with this disease.
Prospective mutational profiling of HCC cases in 
the discovery cohort
Next, we examined the translational application of 
this approach by prospectively studying a cohort of 32 
HCC cases arising from multiple etiologies (discovery 
cohort). The clinical characteristics of these 32 patients are 
summarized in Supplementary Table 3. The majority were 
male (29/32; 90.6%), and the average age of the patients 
was 63.8 years. All patients developed HCC in a cirrhotic 
liver caused by various etiologies: alcohol (12/32; 37.5%), 
hepatitis C virus (11/32; 34.4%), hepatitis B virus (3/32; 
9.4%), hemochromatosis (3/32; 9.4%), hepatitis C virus 
+ alcohol (2/32; 6.25%), and hepatitis B virus + alcohol 
(1/32; 3.2%). The samples were collected consecutively 
at initial stages, mostly from resection (28/32, 87.5%) 
but also from transplantation specimens (4/32, 12.5%). 
To detect somatic mutations in the HepatoExome, we 
compared the mutational data obtained from tumoral 
lesions with that from non-tumoral lesions (cirrhotic liver 
and blood when available). To this end, genomic DNA 
was extracted from paired samples from each patient 
and analyzed using a targeted primary ultrasequencing 
approach, followed by a secondary validation analysis 
(see supplementary methods for further details). These 
processes were completed within 15 days of sample 
reception. Interestingly, we detected somatic mutations 
in 17 of the 32 patients analyzed (53.1%); they had an 
average of 2.1 mutated genes each (Table 1).
Moreover, each patient showed a unique mutational 
profile with individualized combinations of mutations 
and mutated genes. Considered in greater detail, our 
results identified mutant genes that can participate in 
a number of signaling pathways, as would be expected 
from our previous in silico observations. Among these, we 
found mutations affecting WNT-β-CATENIN signaling 
(CTNNB1 in 8/32 of the samples), the MAPK pathway 
(RAF1 and HRAS; 3/32 samples), intracellular calcium 
signaling in 5/32 of the samples (ITPR1 and ITPR2), and 
members of the PI3K/mTOR pathway (MTOR, AKT1 and 
RICTOR; 3/32 samples) (Table 1). Somatic mutations 
were detected with average depths of 420-X and 3.25K-X 
in the primary and validation analyses, respectively.
Thus, it is possible to use this approach to 
characterize cancer lesions in up to 53% of patients with 
HCC with respect to the presence of genomic alterations 
that presumably affect specific signaling mechanisms.
Heterogeneous mechanistic effects on treatment 
with sorafenib in HCC cells
Sorafenib is the only inhibitor used to treat HCC at 
advanced stages in the clinic. We sought to explore the 
effects in proliferation that treatment with this inhibitor 
could elicit in a panel of HCC cell lines. We first performed 
an in silico characterization that enabled the detection of 
mutations in the genes included in the HepatoExome. As 
expected from our previous observations in lesions from 
HCC patients, each cell line showed an individual and 
unique mutational profile (Supplementary Table 4). In this 
setting, the IC50 of sorafenib differed between cell lines 
over a range between 0.5 and 5 μM (Supplementary Figure 
1 and Supplementary Table 4). This observation led us to 
compare the mechanistic effects of sorafenib on the activity 
of some well-known intracellular cancer-related signaling 
pathways using an intracellular pathway array kit (see 
Methods). To this end, we incubated SNU-449, Hep-G2 
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and HUH-7 cells with their specific IC50 concentrations of 
sorafenib. Under these conditions, most of the pathways 
showed no response to this drug, e.g., JAK/STAT, JNK, 
p53, members of the PI3K/mTOR pathways (such as AKT, 
mTOR and PRAS40) or the proapoptotic CASPASE-3 
and PARP (with the exception of P-BAD in Hep-G2 
cells) (Figure 2A and Supplementary Table 5). On the 
other hand, treatment with sorafenib in HCC cells elicited 
heterogeneous inhibitions of ERK1/2 (MAPK) and RPS6 
(S6) phosphorylation (PI3K/mTOR) alongside a consistent 
activation of P-AMPK between cell lines (Supplementary 
Table 5). Since MAPK and PI3K/mTOR are well known 
signaling pathways downstream of the intended molecular 
targets of sorafenib, we sought to confirm these data by 
using an independent approach in a larger panel of HCC 
cells lines. To this end, we performed western blot (WB) 
using lysates from starved cells treated with 1- and 2-fold 
IC50 concentrations of the drug. Confirming our previous 
results, sorafenib displayed differential abilities to inhibit 
the P-MEK and P-ERK signaling pathway in different 
cell lines, independently of the drug concentration (Figure 
2B and 2C). In this regard, the effects of this inhibitor on 
MEK-ERK activity ranged from no inhibition (SNU-449 
cells) through medium (SNU-182) to high (HUH-7) levels 
of inhibition. Finally, under these conditions, sorafenib 
inhibited P-S6 at different intensities (compare the IC50 
responses in SNU-475, Hep-G2 and HUH-7 cells) and 
had no effect on P-AKT (Figure 2B and 2C). Thus, in the 
context of a variety of HCC cell lines, sorafenib elicited 
heterogeneous proliferative and mechanistic responses 
downstream of its intended molecular targets.
Ex vivo effects of targeted therapies guided by 
individual mutational profiles
To gain insights into the biological and mechanistic 
effects that targeted therapy guided by mutational profiles 
could exert in HCC cells, we decided to focus on the 
potentially actionable mutations in our panel of human HCC 
cell lines. Using SNU-449 and HUH-7 cells as examples of 
low or high MAPK inhibition by sorafenib, respectively, 
we first detected mutations in specific genes (and validated 
them by Sanger sequencing; Supplementary Figure 2 and 
Supplementary Table 6). For SNU-449 cells, the mutated 
genes were NTRK1 and PTEN, which were associated 
with the inhibitors lestaurtinib (Cep) and everolimus (Ev) 
respectively (Table 2). In HUH-7 cells, mutated genes 
like INSR, SYK and PIK3C2G were associated with 
fostamatinib (Fos), BMS-754807 (Bms) and buparlisib 
(Bkm) respectively, (Table 2). We then analyzed the anti-
proliferative effects of each inhibitor, in the intended cell 
line, and calculated their IC50 concentrations, using them 
in the subsequent experiments (Table 2). In addition to the 
biological effects observed with targeted drugs, incubation 
of starved cells with 1- or 2-fold IC50 concentrations of each 
drug inhibited downstream signaling pathways associated 
with the activity of the mutated genes (Supplementary 
Figure 3). The biological and mechanistic effects of the 
Figure 1: Molecular heterogeneity detected in silico in 331 HCC lesions with a known mutational profile. (A) In silico 
analysis showing the number of mutations (≥ 4) detected in 331 patients (validation cohorts). (B) Percentage of total hits involved in the 
indicated signaling pathways.
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Table 1: Validated somatic mutations found in the discovery cohort using HepatoExome
Patient Chr. Position Ref. Alt. AA 
change
Gene Coverage Etiology Associated 
therapy
P-01
2 39605221 A T I47K MAP4K3 675
Alcohol
N/A
3 12627258 A C D486E RAF1 576 Selumetinib/Sorafenib
17 7574003 G A R210* TP53 704 N/A
P-02 3 41266110 A C H36P CTNNB1 230 Alcohol N/A
P-05




3 41266100 T G S33A CTNNB1 325 N/A
11 100962605 G T Q434K PGR 206 Mifepristona
12 26749892 G T T1393N ITPR2 502 Tacrolimus/Cyclosporine
22 36696277 C A A958S MYH9 521 N/A
P-10 12 26568307 A G I2412T ITPR2 45 Alcohol Tacrolimus/Cyclosporine
P-11 11 532737 A C Y157D HRAS 1384 Alcohol Selumetinib/Sorafenib
P-13 1 11199401 G A T1697I MTOR 387 HBV Everolimus
P-14 14 105236685 G A T479M AKT1 325 HBV Everolimus/Ipatasertib
P-16 12 26553126 C A V2489L ITPR2 19 Tacrolimus/Cyclosporine
P-17
11 108117799 G A R337H ATM 27
HCV
N/A
11 111625284 T C E196G PPP2R1B 880 N/A
17 7578370 C A Splice TP53 743 N/A
P-18




5 38962438 T C Y565C RICTOR 251 Everolimus
10 43610119 C A G691S RET 697 Regorafenib
17 7577535 C T R117K TP53 666 N/A
20 54961541 A T F311 AURKA 439 Barasertib
P-21 3 41266124 A G T41A CTNNB1 270 HCV N/A
P-22
2 165997273 G C P636R SCN3A 270
HCV
Zonisamida
2 165997274 G T P636T SCN3A 270 Zonisamida
3 41266137 C T Y157D CTNNB1 161 N/A
P-23 3 41266110 A C H36P CTNNB1 161 HCV N/A
P-25 3 41268766 A C K335T CTNNB1 108 HCV N/A
P-26
3 41266113 C A S37Y CTNNB1 87
HCV
N/A
4 55981463 G T N158K KDR 130 Sorafenib
(Continued)
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drugs, used alone or in combinations, were then compared 
in SNU-449 and HUH-7 HCC cells. In these settings, 
all combinations were highly effective at inhibiting cell 
proliferation compared with single treatments, suggesting 
that multiple mechanisms associated with case-specific 
mutations could participate in controlling essential HCC 
activities (Figure 3A and 3B). Furthermore, similar results 
were also obtained in other HCC cell lines like Hep-G2 
(Table 2 and Supplementary Figure 4), SNU-182, SNU-
475 and SNU-423 (Table 2 and Supplementary Figure 5). 
Following the example using SNU-449 and HUH-7 cells, 
we comparatively studied the molecular effects elicited 
by case-specific combinations of targeted therapy over 
multiple signaling pathways simultaneously. Interestingly, 
we only found significant inhibition over the activities 
of MAPK-ERK and a number of AKT/mTOR pathway 
effectors like AKT473, GSK-3B, S6 and PRAS40 (Figure 
3C and Supplementary Table 5). These results were further 
confirmed alongside our panel of six different cell lines, 
each treated with a specific targeted therapy defined by 
their individual mutational signatures (Table 2). In these 
settings, targeted therapy provoked a robust inhibition of 
cell proliferation that occurred alongside a highly significant 
inhibition of PRAS40 and S6 activities, hence suggesting an 
important role for these molecules, which are downstream 
effectors of the AKT/mTOR pathway, in the biology of 
HCC (Figure 3D and Supplementary Table 7).
Biological and mechanistic effects of 
combinations of sorafenib with targeted 
therapies in HCC cell lines
In light of our findings, it is conceivable that 
case-specific targeted therapies could increase the anti-
HCC effects of sorafenib. To explore this possibility, we 
compared the mechanistic effects elicited by incubating 
SNU-449 and HUH-7 cells with IC50 concentrations of 
sorafenib plus cell-specific targeted therapies (see results 
from Hep-G2 cells in Supplementary Figure 4). As 
expected from our previous findings, these combinations 
most strongly inhibited specific signaling mechanisms like 
MAPK-ERK (P-ERK-1/2) and AKT/mTOR (P-AKT473, 
P-GSK-3B and P-PRAS40 and P-S6), which are known to 
play an important role in the biology of HCC (Figure 4A 
and Supplementary Table 5). We next examined our data 
by using an alternative approach to explore the biological 
and mechanistic effects of treatment with sorafenib and 
targeted therapy used alone or in combination in SNU-
449 and HUH-7 cells. The combination of sorafenib with 
targeted drugs most strongly inhibited cell proliferation and 
DNA synthesis in HCC cells (Figures 4B-4E). Interestingly, 
the combination of sorafenib with targeted inhibitors 
caused synergistic effects over the proliferation of SNU-
449 and HUH-7 cells, with combination indexes below 
1 (Supplementary Figure 6). Moreover, this occurred in 
parallel with higher blockages of MAPK and AKT/mTOR 
signaling pathways as assessed by western blot using anti-
P-ERK-1/2, anti-P-AKT473 and anti-P-PRAS40 antibodies 
(Figures 4B-4E). Similar results were also obtained in 
other HCC cell lines like Hep-G2, SNU-182, SNU-475 
and SNU-423 (Supplementary Figures 4 and 5). Finally, 
we interchanged the targeted inhibitors plus sorafenib 
between SNU-449 and HUH-7 cells and analyzed the 
effects in cell proliferation. Our data show higher efficiency 
when inhibitors were used in the appropriate mutational 
background (compare Supplementary Figures 7A with 
4D and Supplementary Figure 7B with 4B). It is therefore 
possible that, using our targeted approach, we could detect 
and target specific mechanisms, like for example AKT/
mTOR, that when used in combination with sorafenib, 
could increase its anti-HCC activities.
DISCUSSION
Considerable effort has been made to determine 
the main mechanisms that may be involved in the 
Patient Chr. Position Ref. Alt. AA 
change
Gene Coverage Etiology Associated 
therapy
P-31
3 41266136 T C S45P CTNNB1 343
Hemochr.
N/A
6 44219910 A T D546V HSP90AB1 934 N/A
P-32
2 165948799 A G I1542T SCN3A 928
Hemochr.
Zonisamida
3 41266101 C G S33C CTNNB1 51 N/A
12 26636635 T C N2003S ITPR2 278 Tacrolimus/Cyclosporine
17 7577094 G A R150W TP53 452 N/A
Patient: Patient number; Chr.: Chromosome number; Position: Genomic location of the mutation in the chromosome; Ref.: 
Normal nucleotide; Alt.: Altered nucleotide; AA change: Amino acid change; Gene: Gene name; Coverage: Number of 
reads analyzed at each position; Etiology: Etiology of each patient; Associated therapy: Possibly Associated Therapy for the 
indicated genes and/or signaling pathways. Hemocrom.: Hemochromatosis.
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pathogenesis and evolution of HCC. Based on the NGS 
data already available in the literature concerning HCC, 
we designed a targeted approach to characterize HCC 
cases from patients with multiple etiologies and in a 
time compatible with the requirements of clinics (within 
15 days). This method enables us to show that sorafenib 
can produce heterogeneous cellular responses in different 
genomic contexts, and that case-specific targeted inhibitors 
can greatly increase its biological and mechanistic anti-
HCC effects.
Taking advantage of the genetically heterogeneous 
nature of HCC, we set up a genomic platform consisting 
of an HCC customized HaloPlexTM enrichment library 
coupled to a MiSeq sequencing system. This enabled 
us to characterize HCC cases (in initial tumors) for the 
presence of somatic mutations in a selection of 112 genes 
cost-effectively and in suitably quick manner to meet 
the requirements of the clinic. We first performed an in 
silico analysis of 331 HCC cases (validation cohort) and a 
prospective ex vivo study of a cohort of 32 paired samples 
(discovery cohort) from multiple etiologies and low-stage 
HCC. Independently of the etiology of the tumor, 60% 
of all cases displayed unique mutational profiles; up to 
34% of the discovery cohort cases had mutated genes 
that could be associated with an inhibitor. In this regard, 
RAF1 (patient-01; sorafenib or selumetinib), MTOR 
(patient-13; everolimus) and RET (patient-18; regorafenib) 
are but three examples of mutated genes potentially 
associated with specific therapy. We might be able to use 
the information obtained by this method to track disease 
progression, for example, using liquid biopsies, and to 
design case-specific approaches for therapy.
Treatment with sorafenib is the standard of care in 
HCC patients with advanced disease (BCLC-C) [9]. It is 
a multi-kinase inhibitor that can target VEGFR, PDFGR, 
c-Kit, c-RAF and B-RAF activities and currently offers 
limited clinical benefits [9, 20]. To study the molecular 
mechanisms targeted by sorafenib in a heterogeneous 
genetic context, we analyzed a panel of HCC cell 
lines, each of which had a unique mutational profile. 
Surprisingly, we found heterogeneous biological responses 
between the cell lines with respect to the range of IC50 
Figure 2: Mechanistic effects of sorafenib in a panel of HCC cell lines. (A) Intracellular signaling array of SNU-449, Hep-G2 
and HUH-7 cells starved and treated for 1h with their IC50 concentration of Sorafenib. (B) Western blotting analyses of SNU-449, Hep-G2, 
SNU-182, SNU-475, SNU-423 and HUH-7 cells starved and treated for 1h with control vehicle (-) and the IC50 and 2x IC50 concentrations 
of sorafenib, as indicated. Cell lysates were incubated with P-MEK1/2, MEK1/2, P-ERK1/2, ERK1/2, P-AKT473, AKT, P-PRAS40, 
PRAS40, P-S6, S6, and α-tubulin antibodies. (C) P-MEK, P-ERK1/2 and P-S6 relative to MEK, ERK1/2 and S6 protein expression in HCC 
cell lines treated with control vehicle, the IC50, and 2 x IC50 concentrations of sorafenib. Error bars show SEM. 
* compared with the control 
vehicle (* P < 0.05; **P < 0.01; ***P < 0.001).
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concentrations observed. In addition, from a mechanistic 
perspective, treatment with sorafenib elicited inhibitory 
responses of different intensities to MAPK-ERK and 
PI3K/mTOR activities depending on the cell line 
tested. On the other hand, we observed steady P-AMPK 
activation, as have previously been described as potential 
mechanisms involved in cellular responses to this drug 
[21, 22]. It is possible that, in different genomic contexts, 
as in this case of HCC cell lines with different mutational 
profiles, the intracellular mechanistic effects elicited by 
sorafenib may vary. It is also conceivable that this could 
be reflected in the heterogeneous population of patients 
Figure 3: Biological effects of combined targeted therapies in HCC cells. (A) Top: Proliferation analysis of SNU-449 cells 
incubated 48h with control vehicle (V, black bar) or the IC50 concentration of the indicated inhibitor (mTORi (Ev: Everolimus) and NTRKi 
(Cep: Lestaurtinib)) alone (dark blue bars) or in a double (light blue bar) combination. Bottom: Western Blotting analyses of SNU-449 
cells starved and treated for 1h with control vehicle or the indicated inhibitor, or the combination of inhibitors under the same conditions 
as above, and incubated with P-S6, S6, P-ERK1/2 and ERK1/2 antibodies. (B) Top: Proliferation analysis of HUH-7 cells at 48h incubated 
with control vehicle (V, black bar) or the IC50 concentration of the indicated inhibitor (SYKi (Fos: Fostamatinib), INSRi (Bms: BMS-
754807) and PIK3R2i (Bkm: Buparlisib)) alone (dark brown bars), or in double or triple combination (light brown bars). Bottom: Western 
Blotting analysis of HUH-7 cells treated for 1h with control vehicle, the indicated inhibitor, or the combination of inhibitors under the same 
conditions as above. P-AKT473, AKT, P-ERK1/2 and ERK1/2, antibodies were used as indicated. (C) Intracellular signaling array of SNU-
449 (left) and HUH-7 (right) cells starved and treated for 1h with control vehicle (black bar) or the combination of IC50 concentration of the 
indicated targeted inhibitors. (D) Proliferation (red bar) and phosphorylation of the indicated antibodies (purple bars) within a panel of six 
HCC cell lines compared to control vehicle (black bar). Error bars show SEM. * compared with the control vehicle (* P < 0.05; **P < 0.01; 
***P < 0.001). # compared with each inhibitor alone (### P < 0.001).
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that are uniformly treated with sorafenib and develop 
variable and unpredictable clinical responses to this drug.
We examined the HepatoExome data obtained in a 
panel of HCC cell lines by analyzing the effects of targeted 
drugs guided by case-specific mutational profiles. We 
found that a rational combination of targeted inhibitors can 
strongly inhibit HCC cell proliferation. Moreover, case-
specific combinatory therapies were highly effective at 
blocking important HCC signaling mechanisms like MAPK 
or AKT/mTOR. In this context, downstream of AKT/mTOR 
signaling axis, we detected two effectors like RPS6 (S6) 
and PRAS40, which were highly dephosphorylated and 
presumably inactivated in response to different targeted 
therapies. Phosphorylation of S6 by p70-S6K has been 
shown to regulate protein synthesis and promote cell 
growth and proliferation by selectively promoting the 
translation of specific mRNAs [23, 24]. PRAS40 can be 
directly phosphorylated by AKT and exert pro-tumorigenic 
activities. Interestingly, in its dephosphorylated form 
PRAS40 negatively regulates mTOR activity which can be 
reversed by direct phosphorylation (reviewed in [25]). It 
is thus possible, that guided by molecular characterization 
of tumor lesions, we could use PI3K, AKT or mTOR 
inhibitors to disrupt AKT/mTOR signaling and inhibit 
S6 and PRAS40 activities as an effective approach to 
treat HCC. We believe this study highlights what targeted 
characterization of specific lesions might offer by way of 
diagnostic possibilities for human hepatocarcinoma in the 
near future. Using early stage hepatocarcinoma samples, 
we found highly heterogeneous genomic landscapes with 
unique mutational signatures. It is conceivable that these 
can trigger aberrant activation of multiple mechanisms 
that may contribute to the pathogenesis and progression 
of each disease. Following this line of evidence, it is also 
possible that upon molecular characterization we could use 
this heterogeneity as a molecular basis to detect specific 
mechanisms promoting HCC progression and resistance to 
treatment and to serve as potential targets for therapy. In 
this regard, multiple clinical trials have been conducted to 
explore the clinical benefit of other drugs when compared, 
Table 2: Potentially actionable mutations found in silico in HCC cell lines and IC50 values associated to them. Table 
showing the mutational characteristics of six commercial cell lines (in silico comparison with Cancer Cell Line 
Encyclopedia (CCLE) data)




4 55976843 A T Y357N KDR KDRi (So) SORAFENIB 3,5
10 43608351 G A D567N RET RETi (Re) REGORAFENIB 3,1




1 156851421 A C D793A NTRK1 NTRKi (Cep) LESTAURTINIB (CEP-701) 1,6
10 89717696 T C F241L PTEN mTORi (Ev) EVEROLIMUS 14,6
HUH-7
9 93606577 A G K133E SYK SYKi (Fos) FOSTAMATINIB 12,9
12 18762561 A C I1394L PIK3C2G PIK3C2Gi (Bkm)
BUPARLISIB 
(BKM-120) 1,7
19 7141798 T C T858A INSR INSRi (Bms) BMS-754807 8,5
SNU-182
3 130409498 T A R1033S PIK3R4 PIK3R4i (Bkm)
BUPARLISIB 
(BKM-120) 0,8
13 29008268 T A E201D FLT1 FLT1i (Re) REGORAFENIB 4,7
19 7184495 G A P269L INSR INSRi (Bms) BMS-754807 1,5
SNU-475 13 28611336 G A T432M FLT3 FLT3i (Cep) LESTAURTINIB (CEP-701) 2,5
SNU-423
3 130452809 C A V345F PIK3R4 PIK3R4i (Bkm)
BUPARLISIB 
(BKM-120) 1,7
13 28913428 C T E789K FLT1 FLT1i (Re) REGORAFENIB 9,5
The table includes Cell line: Cell line name; Chr.: Chromosome number; Position: Genomic location of the mutation in 
the chromosome; Ref.: Normal nucleotide; Alt.: Altered nucleotide; AA Change: Amino acid change; Gene: Gene name; 
Inhibitor name: Used throughout this report; Inhibitor: General name and IC50 (μM): Micromolar IC50 concentration for 
the indicated inhibitor.
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or used in combination, with sorafenib (reviewed in 
[11]). These have yielded poor results that could be 
partially explained by the inclusion of an uncharacterized 
population of patients in the studies. We also explored the 
effects of combinations of sorafenib with case-specific 
inhibitors in a panel of HCC cell lines. In each case, we 
observed greater inhibition of cell proliferation and DNA 
synthesis of the drug combinations (targeted inhibitors + 
sorafenib) compared with sorafenib alone. Intriguingly, 
these inhibitory effects were more evident in HCC cells, 
in which treatment with sorafenib alone inhibited MAPK-
ERK signaling compared with those in which it did not 
Figure 4: Combination of sorafenib and targeted therapy in HCC cells. (A) Intracellular signaling array of SNU-449 (left) 
and HUH-7 (right) cells starved and treated for 1h with control vehicle or the IC50 concentrations of the indicated inhibitors. Proliferation 
analyses of SNU-449 (B, top) and HUH-7 cells (D, top) at 48h incubated with control vehicle (V) or the IC50 concentration of sorafenib 
alone (dark blue and dark brown bars for SNU-449 and HUH-7 cells, respectively), the targeted inhibitors alone (inner squares) or 
combinations of sorafenib with targeted inhibitors (light blue and light brown bars for SNU-449 and HUH-7 cells, respectively). Western 
Blotting analyses of SNU-449 (B, bottom) and HUH-7 (D, bottom) cells starved, treated under the same conditions as above and incubated 
with P-ERK1/2, ERK1/2, P-S6, S6, P-PRAS40, PRAS40, P-AKT473 and AKT antibodies. DNA synthesis assay using Click-iT® EdU in 
SNU-449 (C) and HUH-7 (E) cells incubated for 24h under the same conditions as in B or D respectively. Graph bars show percentage 
of low (light red) or high (intense red) EdU-stained cells in three photographic fields from a representative experiment. Representative 
pictures show the nucleus of the total number of cells (blue dots) and EdU-positive cells (red dots). Statistical analyses of targeted therapy 
or sorafenib plus targeted therapy versus sorafenib alone. Error bars show the SEM. * P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Oncotarget30879www.oncotarget.com
(HUH-7 and SNU-449 cells, respectively; see data in 
Figures 2 and 4). Moreover, our results suggest that targeted 
blockage of MAPK-ERK signaling and AKT/mTOR used 
along with sorafenib can greatly inhibit cell proliferation 
and DNA synthesis of HCC cells. Thus, our results suggest 
that molecular characterization of HCC cases could help 
develop therapies that are more efficient. In this regard, a 
phase II trial of tivantinib used in the second line, showed 
no difference in survival compared with a placebo. This 
inhibitor is currently being tested as a highly selective MET 
inhibitor, although the exact mechanism of action is still 
unclear [26]. Nevertheless, a subgroup of patients with a 
high level of MET expression significantly benefited from 
this treatment although they had worse survival overall; 
a phase III trial in this specific population has since been 
designed [27].
Despite its potential applicability in routine clinical 
practice, our approach requires several limitations to be 
overcome in a similar way to those described in [28]. In 
the case of HCC, a solution would entail: 1) establishing 
efficient protocols to safely collect, manipulate and 
characterize specific lesions that are representative 
of the advanced steps of this disease; 2) considering 
other molecular approaches, such as transcriptome or 
copy number variation studies, in addition to targeted 
mutational analyses; 3) managing the toxicity due to 
drug combinations, particularly given that this disease 
usually appears in the context of a damaged liver; and 4) 
dealing with tumor heterogeneity and interactions with the 
immune system that may be responsible for the resistance 
eventually acquired after combination treatments.
In summary, adopting targeted approaches to 
characterize HCC lesions may make it possible to detect 
specific disease mechanisms, like for example AKT/mTOR, 
that can lead to: 1) develop biomarkers to support diagnosis 
and/or prognosis; 2) serve as targets for specific inhibitors 
rationally combined in individualized therapies to target 
case-specific mechanisms of hepatocyte transformation; and 
3) design more effective combination therapies when used 
with sorafenib in advanced stages of HCC.
MATERIALS AND METHODS
Patient samples
Matched tumoral and non-tumoral samples from 
32 patients with clinically characterized HCC who were 
surgically treated (resection or transplant) were obtained 
retrospectively and prospectively (discovery cohort; 
Supplementary Table 1): 17 patients from Hospital 
Universitario Marqués de Valdecilla (HUMV), Santander; 
and 15 from Hospital Universitario Central de Asturias 
(HUCA), Oviedo. Tumoral DNA samples were obtained 
from freshly frozen (FF) tissue samples and matched non-
tumoral DNA was collected from FF adjacent cirrhotic tissue 
samples and/or peripheral blood from the available patients.
All human samples used in this study were collected 
following the Declaration of Helsinki protocols after 
obtaining written informed consent from each patient 
as required by the CEIC (Comité Ético de Investigación 
Clínica, Cantabria) and the CEAS (Comité de Ética para 
la Atención Sanitaria, Oviedo). No donor organs were 
obtained from executed prisoners or other institutionalized 
persons.
Genomic DNA samples
Genomic DNA was extracted from fresh (blood) 
and/or frozen (cirrhotic and tumoral liver) using 
standard procedures. Briefly, PBS-washed samples, 
were centrifuged and lysed using “Tissue and cell lysis 
solution” buffer for the MasterPureTM kit, complemented 
by proteinase K (5 μl/100 μl buffer) (Epicenter), shaking 
overnight at 56°C. DNA was extracted using phenol/
chloroform/isoamyl alcohol (in proportions of 25:24:1, 
respectively) in a fast Lock Gel Light Eppendorf tube 
(Eppendorf), then washed and precipitated. Genomic DNA 
was quantified using a Qubit ds DNA BR assay kit and a 
Qubit 2.0 fluorimeter (Invitrogen).
Enrichment library design, preparation and 
sequencing
Targeted enrichment sequencing was performed 
on human FF tumor and non-tumor specimen and, when 
indicated, on blood samples. The custom probe design 
was constructed with SureDesign (Agilent Technologies; 
Design ID: 37503-1413372517). The design focused on 
the coding regions of a group of 112 genes known to be 
mutated in HCC, and which were selected based on the 
following criteria: i) genes of known relevance in HCC, 
ii) genes that may be associated with pharmacological 
inhibitors with potential clinical use and iii) genes 
shown mutated in HCC independently of the population 
frequency. DNA libraries were prepared with the HaloPlex 
Target Enrichment System, following the manufacturer’s 
instructions and sequenced as described in [28].
Somatic mutation identification and validation
Somatic mutation identification was done by using 
Agilent Sure Call 2.1.1.13 software and IGV 2.3.46 
software. In parallel Sequencing data were aligned 
against the human reference genome (hg19) using the 
BWA aligner [29]. The alignment was refined using 
SAMTOOLS fixmate and PICARD TOOLS cleanSam 
tools [30], (http://broadinstitute.github.io/picard.). The 
RAMSES application was used to detect nucleotide 
substitutions [31]. For validation, genomic DNA was 
amplified using the specific oligonucleotides described 
in Supplementary Table 5. Samples were prepared and 
analyzed as described in [28].
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Cell cultures and reagents
Six human hepatocellular carcinoma cell lines 
were used. Hep-G2, SNU-449, SNU-475, SNU-423 and 
SNU-182 cells were obtained from the American Type 
Cell Collection (ATCC, Rockville, MD). HUH-7 cells 
were obtained from the Japanese Collection of Research 
Bioresources Cell Bank (JCRB, Japan). Genomic 
data from these cells, including the somatic mutations 
detected in this study, are publicly available at the Broad-
Novartis Cancer Cell Line Encyclopedia website (CCLE: 
http://www.broadinstitute.org). Commercial cell lines 
were cultured as recommended by ATCC or JCRB. 
Hep-G2 and HUH-7 cells were cultured in EMEM 
medium (Lonza, Basel, Switzerland) and SNU-475, 
SNU-449, SNU-423 and SNU-182 cells were cultured in 
RPMI-1640 medium (Lonza, Basel, Switzerland). Both 
mediums were supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (Life Technologies), glucose 
(4.5 g/L), L-glutamine (292 mg/L), streptomycin sulfate 
(10 mg/L) and potassium penicillin (10000 U/L) (Lonza).
To perform functional analysis the following 
inhibitors used in this study were obtained from Selleck 
Chemicals (Houston, TX): BMS-754807, Buparlisib 
(BKM-120), Everolimus (RAD001), Fostamatinib 
(R788), Regorafenib (BAY 73-4506) and Sorafenib; 
and Lestaurtinib (Cep-701) inhibitor were obtained 
from Sigma Aldrich. These drugs were reconstituted in 
Dimethyl Sulfoxide (DMSO) and kept at -20°C until 
use.
Statistics
Unless otherwise specified, all experiments were 
done in independent triplicates and all numerical data were 
summarized as the average of the values ± the standard 
error of the mean (SEM) using GraphPad Prism5 software. 
In Figure 3D and Supplementary Table 6, the significate 
effects of targeted therapy versus control were calculated 
for each cell line. Each global median was compared using 
t-Student test.
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